Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blinded, randomized and placebo controlled trial of Transcrocetinate-sodium to Treat Acute Respiratory Distress Syndrome in COVID-19

Next Previous
Search
Trial Profile

Double-blinded, randomized and placebo controlled trial of Transcrocetinate-sodium to Treat Acute Respiratory Distress Syndrome in COVID-19

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Transcrocetinate sodium (Primary)
  • Indications Adult respiratory distress syndrome; COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors CervoMed; Diffusion Pharmaceuticals

    • Most Recent Events

    • 11 Jun 2020 According to a Diffusion Pharmaceuticals media release, the company expects to file an Investigational New Drug (IND) application later this month.
    • 11 Jun 2020 According to a Diffusion Pharmaceuticals media release, the company intends to combine results from this and from a similar European trial to support the drug's possible approval in both Europe and the U.S.
    • 26 May 2020 According to a Diffusion Pharmaceuticals media release, enrollment in the European arm is expected in June 2020. This is being conducted at Romanian National Institute of Infectious Diseases. The company further expects the European trial to provide first human data regarding TSC oxygenation-enhancing potential in this disease by the end of the summer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top